Literature DB >> 211256

Heterogeneity of Epstein-Barr virus. III. Comparison of a transforming and a nontransforming virus by partial denaturation mapping of their DNAs.

H Delius, G W Bornkamm.   

Abstract

The DNAs of a transforming and a nontransforming Epstein-Barr virus strain, B95-8 AND P3HR-1, were compared by partial denturation mapping. B95-8 viral DNA showed a homogeneous denaturation pattern. In contrast, P3HR-1 viral DNA was heterogeneous, containing at least two classes of molecules, classified into groups A and B and present in a ratio of about 2:1 to 3:1. No evidence could be obtained that molecules from both groups A and B contain identical sequences present in different orientations as described for herpes simplex viral DNA. The majority of sequences present in B95-8 and in P3HR-1 viral DNA group A could be correlated by assuming that different sequences, about 12,000 base pairs long, were inserted or deleted, respectively, at different position of both viral genomes.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 211256      PMCID: PMC354142     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  DNA of Epstein-Barr virus. II. Comparison of the molecular weights of restriction endonuclease fragments of the DNA of Epstein-Barr virus strains and identification of end fragments of the B95-8 strain.

Authors:  S D Hayward; E Kieff
Journal:  J Virol       Date:  1977-08       Impact factor: 5.103

2.  Heterogeneity of Epstein-Barr virus originating from P3HR-1 cells. I. Studies on EBNA induction.

Authors:  K O Fresen; B Merkt; G W Bornkamm; H Hausen
Journal:  Int J Cancer       Date:  1977-03-15       Impact factor: 7.396

3.  Heterogeneity of Epstein-Barr virus. II. Induction of early antigens (EA) by complementation.

Authors:  H zur Hausen; K O Fresen
Journal:  Virology       Date:  1977-08       Impact factor: 3.616

4.  Herpesvirus ateles DNA and its homology with Herpesvirus saimiri nucleic acid.

Authors:  B Fleckenstein; G W Bornkamm; C Mulder; F J Werner; M D Daniel; L A Falk; H Delius
Journal:  J Virol       Date:  1978-01       Impact factor: 5.103

5.  A partial denaturation map of herpes simplex virus type 1 DNA: evidence for inversions of the unique DNA regions.

Authors:  H Delius; J B Clements
Journal:  J Gen Virol       Date:  1976-10       Impact factor: 3.891

6.  Base specific fractionation of double stranded DNA: affinity chromatography on a novel type of adsorbant.

Authors:  H Bünemann; W Müller
Journal:  Nucleic Acids Res       Date:  1978-03       Impact factor: 16.971

7.  Epstein-Barr virus-induced transformation of human leukocytes after cell fractionation.

Authors:  U Schneider; H zur Hausen
Journal:  Int J Cancer       Date:  1975-01-15       Impact factor: 7.396

8.  Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference.

Authors:  G Miller; J Robinson; L Heston; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

9.  Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.

Authors:  Y Hinuma; M Konn; J Yamaguchi; D J Wudarski; J R Blakeslee; J T Grace
Journal:  J Virol       Date:  1967-10       Impact factor: 5.103

10.  Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum antibody responses, demonstration of viral DNA, and characterization of viruses.

Authors:  G Miller; T Shope; D Coope; L Waters; J Pagano; G Bornkamn; W Henle
Journal:  J Exp Med       Date:  1977-04-01       Impact factor: 14.307

View more
  39 in total

1.  DNA of Epstein-Barr virus. VI. Mapping of the internal tandem reiteration.

Authors:  D Given; E Kieff
Journal:  J Virol       Date:  1979-08       Impact factor: 5.103

2.  Sites of sequence variability in Epstein-Barr virus DNA from different sources.

Authors:  L Rymo; T Lindahl; A Adams
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

3.  Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines.

Authors:  J Finke; M Rowe; B Kallin; I Ernberg; A Rosén; J Dillner; G Klein
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

4.  Biochemical characterization of Epstein-Barr virus nuclear antigen 2A.

Authors:  F A Grässer; P Haiss; S Göttel; N Mueller-Lantzsch
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  A replication function associated with the activation domain of the Epstein-Barr virus Zta transactivator.

Authors:  R T Sarisky; Z Gao; P M Lieberman; E D Fixman; G S Hayward; S D Hayward
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

6.  Two strains of Epstein-Barr virus (B95-8 and a P3HR-1 subclone) that lack defective genomes induce early antigen and cause abortive infection of Raji cells.

Authors:  J C Lin; N Raab-Traub
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

7.  Amplification of Epstein-Barr virus (EBV) DNA by superinfection with a strain of EBV derived from nasopharyngeal carcinoma.

Authors:  H Sato; T Takimoto; J S Pagano; N Raab-Traub
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

8.  Mapping of genes in BamHI fragment M of Epstein-Barr virus DNA that may determine the fate of viral infection.

Authors:  J Sample; G Lancz; M Nonoyama
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

9.  Points of recombination in Epstein-Barr virus (EBV) strain P3HR-1-derived heterogeneous DNA as indexes to EBV DNA recombinogenic events in vivo.

Authors:  Kazufumi Ikuta; Shamala K Srinivas; Tim Schacker; Jun-ichi Miyagi; Rona S Scott; John W Sixbey
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

10.  Structure of defective DNA molecules in Epstein-Barr virus preparations from P3HR-1 cells.

Authors:  M S Cho; G W Bornkamm; H zur Hausen
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.